Tykodi, Scott S.

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 7,945

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 5,807

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Motzer, R. J., Rini, B. I., McDermott, D. F., Arén Frontera, O., Hammers, H. J., Carducci, M. A., Salman, P., Escudier, B., Beuselinck, B., Amin, A., et al. (2019) · The Lancet Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 775

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Diab, A., Tannir, N. M., Bentebibel, S.-E., Hwu, P., Papadimitrakopoulou, V., Haymaker, C., Kluger, H. M., Gettinger, S. N., Sznol, M., Tykodi, S. S., et al. (2020) · Cancer Discovery

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 237

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Motzer, R. J., Escudier, B., McDermott, D. F., Arén Frontera, O., Melichar, B., Powles, T., Donskov, F., Plimack, E. R., Barthélémy, P., Hammers, H. J., et al. (2020) · Journal for ImmunoTherapy of Cancer

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 224

Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system

Miller, C. P., Fung, M., Jaeger-Ruckstuhl, C. A., Xu, Y., Warren, E. H., Akilesh, S., & Tykodi, S. S. (2023) · Neoplasia

3D Printing in Biomedical ResearchCancer Cells and Metastasis

Cited by 19